Kidney Therapeutics to Halt CKD Progression, Make Late-Stage Push Toward NDA

This week's American Society of Nephrology (ASN) meeting highlighted therapeutics to halt the progression of chronic kidney disease (CKD) currently in late-phase clinical trials. NDAs could be filed for some of these drugs as early as 2024, with regulatory determinations as early as 2025.